$アタラ バイオセラピューティクス(ATRA.US)$PAY VERY CLOSE ATTENTION TO THE LAST 3 BULLET POINTS! This could be a catalyst for a large price increase? Even if its only a temporary increase? I want you to have ample opportunity to catch ahead of time if YOU CHOOSE? Not me choosing for YOU! NFA! Just a heads up for the possibility! Tab-cel U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Me...
10
15
報告
Benjamin’s :
This for tomorrow or just reminder,? I didn’t see date.? TIA
$アタラ バイオセラピューティクス(ATRA.US)$Tab-cel U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans To Initiate a ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025 ATA3219 NHL Study Enrolling With Initial Clinical Data Expected in Q4 2024 Cash Runway Into 2027 Enables Key Pipeline Readouts
4
1
報告
Trytosaveabitスレ主SpyderCall:
GM! Hope you’re having a great weekend! Yes that’s pretty encouraging, I believe! I thank you for sharing!
$アタラ バイオセラピューティクス(ATRA.US)$Atara Biotherapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Citadel Advisors LLC(6.4%),Citadel Advisors Holdings LP(6.4%), etc. SEC announcement· 4 mins ago
$アタラ バイオセラピューティクス(ATRA.US)$Atara Biotherapeutics Submits New Drug Application to FDA for ATA3219 to Treat Lupus Nephritis MT Newswires· 4 mins ago Atara Biotherapeutics (ATRA) said Wednesday it submitted an investigational new drug application to the US Food and Drug Administration seeking approval for ATA3219 as a standalone treatment for systemic lupus erythematosus, or lupus nephritis that affects the kidneys. ATA3219 is an allogeneic chimeric antigen receptor T-cell therapy that ...
$アタラ バイオセラピューティクス(ATRA.US)$Atara Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(6.56%) SEC announcement· 7 mins ago
アタラ バイオセラピューティクスに関するコメント
Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans To Initiate a ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025
ATA3219 NHL Study Enrolling With Initial Clinical Data Expected in Q4 2024
Cash Runway Into 2027 Enables Key Pipeline Readouts
SEC announcement· 4 mins ago
Moomoo 24/7· 1 min ago
SEC announcement· 16:29
MT Newswires· 4 mins ago
Atara Biotherapeutics (ATRA) said Wednesday it submitted an investigational new drug application to the US Food and Drug Administration seeking approval for ATA3219 as a standalone treatment for systemic lupus erythematosus, or lupus nephritis that affects the kidneys.
ATA3219 is an allogeneic chimeric antigen receptor T-cell therapy that ...
SEC announcement· 7 mins ago
まだコメントはありません